Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) CEO Sanj Patel sold 121,248 shares of the business’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $38.90, for a total value of $4,716,547.20. Following the sale, the chief executive officer directly owned 111,794 shares of the company’s stock, valued at $4,348,786.60. This represents a 52.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Kiniksa Pharmaceuticals International Stock Performance
NASDAQ:KNSA opened at $38.90 on Thursday. The stock has a 50-day simple moving average of $36.20 and a two-hundred day simple moving average of $30.08. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $39.79. The firm has a market capitalization of $2.88 billion, a PE ratio of 972.74 and a beta of 0.16.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on KNSA
Institutional Investors Weigh In On Kiniksa Pharmaceuticals International
A number of hedge funds have recently made changes to their positions in the company. Rubric Capital Management LP lifted its position in shares of Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after buying an additional 526,567 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Kiniksa Pharmaceuticals International by 4.7% in the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock worth $74,606,000 after buying an additional 151,604 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 22.6% in the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock worth $35,067,000 after buying an additional 233,668 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in shares of Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after buying an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after buying an additional 67,452 shares in the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Featured Articles
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Financial Services Stocks Investing
- Archer’s Recent String of Victories Signals a New Phase of Growth
- What is a Secondary Public Offering? What Investors Need to Know
- 3 Key Stocks Boosting Buybacks Amid Improving Fundamentals
- Compound Interest and Why It Matters When Investing
- The Best AI for Picking Stocks, Ranked by Performance
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.